This clinical trial is focused on studying the effectiveness and safety of a medication called elinzanetant for treating hot flashes in women who are either undergoing or at high risk for developing hormone-receptor positive breast cancer. Hot flashes are sudden feelings of warmth, often associated with sweating, that can be caused by certain cancer treatments known as adjuvant endocrine therapy. This study aims to see how well elinzanetant works in reducing these symptoms compared to a placebo, which is a substance with no active medication.

Participants in the study will be randomly assigned to receive either elinzanetant or a placebo. The study will last for 52 weeks, with an option to continue for an additional two years. During this time, participants will take the medication in the form of soft capsules by mouth. The study will monitor changes in the frequency and severity of hot flashes over time, as well as any effects on sleep and quality of life.

The goal of the study is to provide more information about how elinzanetant can help manage hot flashes in women affected by hormone-receptor positive breast cancer treatments. By comparing the results between those taking elinzanetant and those taking a placebo, researchers hope to better understand the potential benefits and safety of this treatment option.